Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma (iCCA)

From Startup ARQULE Link to Full Article: 21% objective response rate with six confirmed partial responses from 29 evaluable patients 83% disease control rate Safety profile and tolerability of continuous dosing schedule confirmed BURLINGTON, Mass.–(BUSINESS WIRE)–Jan. 9, 2019– ArQule, Inc.’s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), today announced results

Genevant Appoints Dr. Margrit Schwarz as Chief Scientific Officer and Head of R&D, and Pete Zorn as Chief Operating Officer

From Startup Genevant Link to Full Article: https://genevant.com/genevant-appoints-dr-margrit-schwarz-as-chief-scientific-officer-and-head-of-rd-and-pete-zorn-as-chief-operating-officer/ Additions bolster Genevant’s leadership position in the RNA therapeutics space with its multiple modality, “pan-RNA” approach BOSTON, MASSACHUSETTS; BURNABY, CANADA; and BASEL, SWITZERLAND – January 7, 2019 – Genevant Sciences, a leading biopharmaceutical company focused on the discovery and development of a

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises

From Startup Heron Therapeutics Link to Full Article: https://herontherapeutics.gcs-web.com/news-releases/news-release-details/heron-therapeutics-highlights-progress-pain-management-and-cinv SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlighted progress in its

AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors

From Startup Avrobio Link to Full Article: Industry leader brings global expertise, including as Shire’s former Global Head of Research and Development, to help further accelerate momentum and growth CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) — AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company, today announced

Clinithink secures growth-equity investment to fuel growth

From Startup Clinithink Link to Full Article: https://clinithink.com/clinithink-secures-growth-equity/ Leading healthcare technology investors partner with Clinithink to unlock the potential of unstructured data to inform treatment decisions, identify candidates for clinical trials, and ensure appropriate reimbursement   Clinithink, which offers healthcare and life sciences organizations powerful clinical data insights through its

Sigilon Therapeutics and MIT Announce Research Collaboration to Advance Programmable Living Therapeutics for Serious Chronic Diseases

From Startup Sigilon Therapeutics Link to Full Article: http://sigilon.com/2019/01/07/sigilon-therapeutics-and-mit-announce-research-collaboration-to-advance-programmable-living-therapeutics-for-serious-chronic-diseases/ CAMBRIDGE, Mass. — January 7, 2019 — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops Shielded Living Therapeutics, and the Massachusetts Institute of Technology today announced a strategic research collaboration. The collaboration leverages cutting-edge synthetic biology approaches developed by professor Ron Weiss

https://decibeltx.com/wp-content/uploads/2019/01/Decibel_Cocoon-Press-Release-Jan-7-2019-1.pdf

From Startup Decibal Therapeutics Decibel Therapeutics has established the world’s first comprehensive drug discovery, development, and translational research platform to discover and develop the first therapeutics to protect, repair, and restore hearing. To serve the over half billion people globally living with hearing loss and related disorders, Decibel is committed

Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome

From Startup Urovant Link to Full Article: https://urovant.com/2019/01/04/urovant-sciences-initiates-patient-enrollment-in-phase-2a-clinical-trial-for-vibegron-in-patients-with-abdominal-pain-due-to-irritable-bowel-syndrome/ BASEL, Switzerland & IRVINE, Calif.–(BUSINESS WIRE)–Jan. 3, 2019– Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, announced the company enrolled its first patient in a Phase 2a clinical trial evaluating vibegron in patients with

Neon Therapeutics Provides Business Update and Outlook for 2019

From Startup Neon Therapeutics Link to Full Article: CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today provided a business update and outlook for 2019. “We have an exciting year ahead of us in 2019, with multiple data